Prosecution Insights
Last updated: August 13, 2026
Application No. 18/282,083

BIARYL AMIDE AND HETEROARYL AMIDES FOR TREATMENT OF CANDIDA ALBICANS INFECTION

Final Rejection §112
Filed
Sep 14, 2023
Priority
Mar 15, 2021 — provisional 63/161,124 +1 more
Examiner
LEESER, ERICH A
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Board of Regents of the University of Texas System
OA Round
2 (Final)
82%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
782 granted / 958 resolved
+21.6% vs TC avg
Moderate +14% lift
Without
With
+13.5%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
29 currently pending
Career history
980
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
14.7%
-25.3% vs TC avg
§102
23.7%
-16.3% vs TC avg
§112
39.9%
-0.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 958 resolved cases

Office Action

§112
DETAILED ACTION This action is in response to Applicant’s submission dated June 1, 2026, in which Applicant amended claims 1, 4, 6, and 21, and canceled claims 2, 8, and 22-29. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112(d): Claims 1 is rejected under 35 U.S.C. 112(b), as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 is rejected under 35 U.S.C. 112(b) because the structure of Formula I contains X1 to X3; however, in the prose defining each, there is an extra definition for X4 too that is extraneous. Correction is required. Claim Objections Claims 4, 6, 10, 12-15, and 20-21 are objected to as being dependent upon rejected independent claim 1, but would be allowable if rewritten in independent form including all of the limitations of the base claims and any intervening claims. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion Any inquiry concerning this communication or earlier communications from the Examiner should be directed to ERICH A LEESER whose telephone number is (571) 272-9932. The Examiner can normally be reached Monday through Friday from 10-6 PST, M-F. PST. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Mr. James Alstrum-Acevedo can be reached at (571) 272-5548. The fax number for the organization where this application is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) toll-free at 866-217-9197. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICH A LEESER/Primary Examiner, Art Unit 1622 United States Patent and Trademark Office Tel. No.: (571) 272-9932
Read full office action

Prosecution Timeline

Sep 14, 2023
Application Filed
Apr 29, 2026
Non-Final Rejection mailed — §112
Jun 01, 2026
Response Filed
Jun 17, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703703
FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF
3y 7m to grant Granted Aug 11, 2026
Patent 12697324
USE OF COMPOUND AS CYP2E1 INHIBITOR
3y 5m to grant Granted Aug 04, 2026
Patent 12691119
METHODS FOR TREATING COVID-19 WITH SEPIAPTERIN
2y 11m to grant Granted Jul 28, 2026
Patent 12673042
[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS
3y 2m to grant Granted Jul 07, 2026
Patent 12661330
MIRDAMETINIB TREATMENT
2y 3m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
82%
Grant Probability
95%
With Interview (+13.5%)
2y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 958 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month